The Venture Codex

Participated · Seed · Jul 2026

Rivus Batteries develops an organic variant of flow batteries designed for stationary, large-scale energy storage applications such as grid installations and datacenters. The company highlights that its chemistry avoids the use of critical metals. Founded and operating in Gothenburg, Rivus has spent three years developing its technology. With the new investment from Turbine Capital and Almi Invest Greentech, Rivus plans to optimize and scale up its manufacturing process. The company aims to commercialize the scaled manufacturing for deployment in large, fixed installations. The article does not disclose revenue, user metrics, prior funding amounts, or valuation.

Led · Seed · Jun 2026

Epitome Therapeutics is developing a proprietary epigenome editing platform called CADENCE that aims to enable precise, durable and calibrated activation of gene expression without changing DNA sequence. The platform uses a modular architecture built around a library of engineered epigenetic effectors intended to tailor gene activation to specific biological contexts. The company was founded in 2025 as a spin-off from EMBL and is focused on translating its science into development programmes and selecting a first drug candidate. Financially, Epitome closed a €4 million pre-seed financing (€2M equity plus €2M grants) to advance the platform and grow its team. The company plans to use the new capital to advance development programmes and expand its headcount as it progresses toward initial therapeutic milestones.

Participated · Seed · Jun 2026

Ora Computing builds software and algorithms to compress and optimise AI foundation models, claiming up to 80% model size reduction and up to fourfold inference speedups while typically keeping accuracy losses between 0 and 5%. Its technology integrates with standard inference frameworks and operates across hardware platforms without requiring custom software layers, infrastructure changes, or capital-intensive retraining. The company demonstrated compressing a 70-billion-parameter model within hours at a compute cost below $1,000, and estimates that 1% market penetration could save over 50,000 tonnes of CO₂ annually. Ora targets cloud inference providers and organisations deploying AI at the edge, and plans to use the new funding to expand the team, extend compression capabilities for the largest models, and launch a commercial product. Stefan Sack is cited as CEO and co-founder.

Participated · Seed · Jun 2026

CollimateHealth develops microbeam radiation therapy using arrays of X-ray beams only tens of micrometres wide to induce tumour cell death and stimulate an immune response. The company emerged from almost a decade of research at the Technical University of Munich and was co-founded in 2025 by Stefan Bartzsch and Johanna Winter. CollimateHealth reports it has miniaturized the beamline required for microbeam delivery to under 10 square metres, aiming to enable clinical deployment beyond large synchrotron facilities. The startup closed an oversubscribed €6 million seed round from five European life-sciences investors to fund its first clinical prototype and the preclinical work needed for regulatory filings. It partners with clinical and research institutions including TUM University Hospital rechts der Isar, Helmholtz Institute Mainz, Forschungszentrum Jülich, the Institute of Cancer Research, and The Royal Marsden Hospital. The company plans to treat its first patients by the end of 2028 and has won awards such as the Falling Walls Award and the MedTech Ideator Award at Best of Biotech Vienna in 2025.

Led · Seed · Jun 2026

Invisible-Light Labs commercialises nanoelectromechanical Fourier-transform infrared spectroscopy (NEMS‑FTIR) to chemically analyse sub-micron particles, aerosols, nanoplastics and samples available in very limited quantities. Its flagship product, EMILIE (also sold jointly with Bruker Optics as BRKR-EMILIE), is a commercially available analyzer that combines nanomechanical sensing with FTIR spectroscopy. The company targets applications across environmental monitoring, pharmaceutical analysis, and nanotechnology. Founded in 2019 as a TU Wien spin-out, Invisible-Light Labs signed a strategic partnership with Bruker Optics in 2025 to expand global availability of its system. The company recently raised €1.5 million in a pre-seed round to accelerate international commercialisation and to fund development of additional products for its target markets.